News & Events
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
Crinetics Pharmaceuticals management to participate in a fireside chat at the 2022 JMP Securities Life Sciences Conference
READ MORECrinetics Reports Top-line CRN04894 MAD Results from Phase 1 Study
Crinetics Reports Top-Line Phase 1 MAD results showing CRN04894 suppresses cortisol even in presence of disease-like ACTH concentrations
READ MORECrinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Crinetics reported financial results for the first quarter 2022 and outlined recent progress, including Phase 1 readout from CRN04777, licensing agreement with SKK, and strengthened management team and balance sheet.
READ MORECrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals Announces Inducement Grants The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORECrinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
Crinetics closed an underwritten public offering of 5,625,563 shares of its common stock, resulting in gross proceeds of approximately $125. 0 million.
READ MORECrinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22. 22 per share.
READ MORECrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
